Gilead Sciences (GILD) CEO sells 15,000 shares under Rule 10b5-1 plan

Q: What insider transaction did Gilead Sciences (GILD) report for Daniel O'Day?

Gilead Sciences reported that Daniel O'Day , its chairman and CEO, sold 15,000 shares of common stock on August 3, 2026. The Form 4 lists three separate transactions, all involving sales of Gilead common shares.

Q: How many GILD shares did CEO Daniel O'Day sell and on what date?

CEO Daniel O'Day sold a total of 15,000 Gilead Sciences (GILD) shares on August 3, 2026 . The sales were reported as three non-derivative transactions in Gilead common stock on the same trading date.

Q: At what prices were Daniel O'Day’s Gilead (GILD) shares sold?

The Form 4 reports sales at $129.6583 , $130.8022 , and $131.3433 per share, with execution prices ranging from $129.17 to $130.16 , $130.18 to $131.17 , and $131.21 to $131.47 per share for the respective transaction groups.

Q: What type of security did Daniel O'Day sell in the Gilead (GILD) Form 4?

All reported transactions involve Gilead Sciences common stock . The Form 4 lists three non-derivative sales of common shares, described as occurring through open market or private transactions, rather than involving options or other derivative securities.

Q: How many separate transactions are reported in Daniel O'Day’s latest GILD Form 4?

The Form 4 reports three separate non-derivative transactions in Gilead common stock on August 3, 2026. Together these transactions total 15,000 shares sold , broken into blocks of 6,700 shares, 7,700 shares, and 600 shares.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Gilead Sciences chairman and CEO Daniel O'Day reported selling 15,000 shares of common stock on August 3, 2026, in three transactions described as open market or private at reported prices of $129.6583, $130.8022, and $131.3433 per share. The sales were executed under a Rule 10b5-1 trading plan adopted on February 25, 2026, with execution prices in ranges from $129.17 to $130.16, $130.18 to $131.17, and $131.21 to $131.47 per share.

Insights

Analyzing...

Insider Trade Summary 10b5-1

Net Seller: 15,000 shares

Net Sell 3 txns

Insider O'Day Daniel Patrick

Role Chairman & CEO

Sold 15,000 shs ($1.95M)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	6,700	$129.6583	$869K
Sale	Common Stock ^{F1, F3}	7,700	$130.8022	$1.01M
Sale	Common Stock ^{F1, F4}	600	$131.3433	$79K

Holdings After Transaction: Common Stock — 592,133 shares (Direct)

Footnotes (4)

F1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
F2. Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F3. Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
F4. Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Key Figures

Shares sold: 15,000 shares First transaction size: 6,700 shares Second transaction size: 7,700 shares +5 more

8 metrics

Shares sold 15,000 shares Total Gilead Sciences common shares sold by Daniel O'Day on 2026-08-03

First transaction size 6,700 shares Common stock sold at a reported $129.6583 per share on 2026-08-03

Second transaction size 7,700 shares Common stock sold at a reported $130.8022 per share on 2026-08-03

Third transaction size 600 shares Common stock sold at a reported $131.3433 per share on 2026-08-03

Price range first group $129.17 to $130.16 per share Execution price range for the first set of reported sales

Price range second group $130.18 to $131.17 per share Execution price range for the second set of reported sales

Price range third group $131.21 to $131.47 per share Execution price range for the third set of reported sales

Rule 10b5-1 plan adoption date February 25, 2026 Date the trading plan covering these sales was adopted

Key Terms

Rule 10b5-1 trading plan, Form 4, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Form 4 regulatory

"The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open market or private transaction financial

"Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 05:41 PM Accepted by SEC EDGAR 08/04/2026 - 05:40 PM

FAQ

What insider transaction did Gilead Sciences (GILD) report for Daniel O'Day?

Gilead Sciences reported that Daniel O'Day, its chairman and CEO, sold 15,000 shares of common stock on August 3, 2026. The Form 4 lists three separate transactions, all involving sales of Gilead common shares.

How many GILD shares did CEO Daniel O'Day sell and on what date?

CEO Daniel O'Day sold a total of 15,000 Gilead Sciences (GILD) shares on August 3, 2026. The sales were reported as three non-derivative transactions in Gilead common stock on the same trading date.

At what prices were Daniel O'Day’s Gilead (GILD) shares sold?

The Form 4 reports sales at $129.6583, $130.8022, and $131.3433 per share, with execution prices ranging from $129.17 to $130.16, $130.18 to $131.17, and $131.21 to $131.47 per share for the respective transaction groups.

Was Daniel O'Day’s Gilead (GILD) stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026. This indicates the sales followed a pre-established trading arrangement rather than being initiated spontaneously.

What type of security did Daniel O'Day sell in the Gilead (GILD) Form 4?

All reported transactions involve Gilead Sciences common stock. The Form 4 lists three non-derivative sales of common shares, described as occurring through open market or private transactions, rather than involving options or other derivative securities.

How many separate transactions are reported in Daniel O'Day’s latest GILD Form 4?

The Form 4 reports three separate non-derivative transactions in Gilead common stock on August 3, 2026. Together these transactions total 15,000 shares sold, broken into blocks of 6,700 shares, 7,700 shares, and 600 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Day Daniel Patrick

(Last)

(First)

(Middle)

333 LAKESIDE DRIVE

(Street)

FOSTER CITY

CALIFORNIA

94404

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/03/2026		S⁽¹⁾		6,700	D	$129.6583⁽²⁾	600,433	D
Common Stock	08/03/2026		S⁽¹⁾		7,700	D	$130.8022⁽³⁾	592,733	D
Common Stock	08/03/2026		S⁽¹⁾		600	D	$131.3433⁽⁴⁾	592,133	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.

2. Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

3. Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

4. Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.

Remarks:

	/s/ Amy Kim by Power of Attorney for Daniel O'Day	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR